Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy

Eur J Ophthalmol. 2011 Jul-Aug;21(4):503-5. doi: 10.5301/EJO.2011.6290.

Abstract

Purpose: To report the anatomic and functional outcome of intravitreal bevacizumab (IVB) to treat choroidal neovascularization (CNV) following photodynamic therapy (PDT) to treat recurrent central serous choroidopathy (CSC).

Methods: This was an interventional case report in which verteporfin PDT was performed in a case of recurrent CSC.

Results: Following PDT, the patient developed juxtafoveal CNV that was later treated by IVB, achieving CNV closure and recovery of visual acuity.

Conclusions: Photodynamic therapy is a useful therapy to treat recurrent CSC, though it may be associated with potentially severe complications such as CNV. Intravitreal bevacizumab seems a good alternative treatment in the management of this condition.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / administration & dosage*
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Bevacizumab
  • Central Serous Chorioretinopathy / drug therapy*
  • Central Serous Chorioretinopathy / physiopathology
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Choroidal Neovascularization / physiopathology
  • Combined Modality Therapy
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Male
  • Photochemotherapy / adverse effects*
  • Photosensitizing Agents / therapeutic use
  • Porphyrins / therapeutic use
  • Recurrence
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Verteporfin
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Photosensitizing Agents
  • Porphyrins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Verteporfin
  • Bevacizumab